EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Tag

gastroenterology

Houston Consensus Shrinks Gaps in H. Pylori Management

“There are clear gaps in testing, treatment, and follow-up for H pylori in North America, and we wanted to release a consensus...

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 338
Millbrae, CA 94030

For Deliveries:
Gastric Cancer Foundation
501 Broadway, #338
Millbrae, CA 94030-1907

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

17 hours ago

Recent research in India finds that molecular testing for advanced gastric cancer unveils important markers, paving the way for personalized treatments and improved outcomes. ... See MoreSee Less

Molecular Testing in Stage 4 Stomach Cancer in India: A Single-Centre Experience

www.cureus.com

Introduction Advanced gastric cancer (GC) has a very poor prognosis, and chemotherapy has been the standard of care. The use of immunotherapy or targeted therapy in the stage 4 setting is dependent on...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

3 days ago

Foundation board member chef Hans Rueffert has found a new love for kombucha. Sip on this bubbly drink to populate your gut with armies of bacteria that will help you break down difficult-to-digest food. ... See MoreSee Less

Episode 59: Tips for Everyday Eating - Kombucha

www.youtube.com

Foundation board member and "Chef without a Stomach" Hans Rueffert inspires and encourages anyone with special digestive needs to never hesitate to try new ...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

5 days ago

A study from the National Hospital of Sri Lanka reveals that delayed patient presentation and initiation of treatment significantly impact survival in gastric adenocarcinoma; findings emphasize the need for public health interventions to minimize delays and improve outcomes. ... See MoreSee Less

Delay in diagnosis to treatment and impact on survival of gastric adenocarcinoma in a low income setting without screening facility - Scientific Reports

www.nature.com

The treatment modality of gastric adenocarcinoma (GCA) depends on the stage of the disease at the clinical presentation. Long delays are probably an unfavorable factor for the patient's prognosis. A p...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

5 days ago

What's the best way to find out about clinical trials in gastric cancer? Our free no-obligation clinical trial matching service is a quick phone call away. Speak with a trained navigator by calling 1-855-731-6032 on weekdays, 8am-6pm ET. ... See MoreSee Less

Clinical Trial Finder | Gastric Cancer Foundation

gastriccancer.org

Our free no-obligation clinical trial finder helps match you with appropriate clinical trials in your area. Trained navigators are also available via phone call to help you prepare to discuss clinical...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 week ago

A new study reveals potential in targeting Claudin 18.2 for treating resectable gastric cancer, with 46.5% of patients showing overexpression, associated with unique clinicopathologic features. ... See MoreSee Less

Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer - Scientific Reports

www.nature.com

Claudin 18.2 has emerged as a promising therapeutic target in gastric cancer based on phase 3 studies. However, clinicopathologic features associated with claudin 18.2 overexpression have not been com...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

X